Repros Therapeutics Inc (RPRX)

[DewDiligence]

[OT] >[MNTA] fell to $4 on the NOT APPROVABLE decision. They had over $3 in cash at that point. Now the stock is $8 and they have less than $3 in cash, pro forma for Oct-Feb burn and a more reasonable payables #. How are they not going to have to do more trials if ENCY, in the same position as them (said no new trials, FDA said yes to new trials and FDA WON), got an APPROVABLE LETTER and still lost and had to do new trials. Other stuff is preclin. EMIS, FLML and other "formulations" people have had no success. I think it goes to $2 in a year or so.<

There is no such thing as an approvable letter for an ANDA.

Is it typical for you to short a stock where you have done essentially zero DD on the company?